Special items: Ovarian Cancer and Us blog best viewed in Firefox

Friday, June 03, 2011

press release: EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients Phase 2 Data Presented in ASCO Poster Discussion Session

phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.